<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In this issue El-Serag et al. present a retrospective study which shows that patients with <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> and no <z:mpath ids='MPATH_589'>dysplasia</z:mpath> who were prescribed <z:chebi fb="4" ids="53266">PPIs</z:chebi> had a lesser rate of developing <z:mpath ids='MPATH_589'>dysplasia</z:mpath> than patients who were not prescribed <z:chebi fb="4" ids="53266">PPIs</z:chebi> </plain></SENT>
<SENT sid="1" pm="."><plain>Acid suppression has been proposed both as a cause and a cure for the "epidemic" of <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> of the esophagus, which has been noted in the United States </plain></SENT>
<SENT sid="2" pm="."><plain>The article and the current evidence related to acid suppression and <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> of the esophagus are reviewed </plain></SENT>
</text></document>